参考文献/References:
[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3):209-249.
[2]中华人民共和国国家卫生健康委员会.乳腺癌诊疗指南(2022年版).中国合理用药探索,2022,19(10):1-26.
[3]Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol,2020,60:14-27.
[4]Mal R, Magner A, David J, et al. Estrogen receptor beta (ERβ): A ligand activated tumor suppressor. Front Oncol,2020,10:587386.
[5]Ryu KJ, Kim MS, Lee JY, et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw Open,2022,5(11):e2243951.
[6]Lin XL, Zhang DS, Ju ZY, et al. Diagnostic value of different color ultrasound diagnostic method in endometrial lesions. World J Clin Cases,2021,9(19):5037-5045.
[7]Jaboński K, Kurek , ukowski M, et al. Elastography of endometrium in women taking tamoxifen: A new approach to an old diagnostic problem. J Clin Med,2020,9(12):3870.
[8]Jo HB, Lee HJ, Kim SC, et al. Evaluation of endometrial thickness in breast cancer patients with tamoxifen treatmentdifference between 2dimensional ultrasonography and elastosonography. Taiwan J Obstet Gynecol,2023,62(4):547-552.
[9]Chiofalo B, Mazzon I, Di Angelo Antonio S, et al. Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies: Results from a large multicenter cohort study. J Minim Invasive Gynecol,2020,27(4):832-839.
[10]Zhang G, Yu X, Sun Z, et al. Value of endometrial thickness in diagnosis of endometrial hyperplasia during selective estrogen receptor modulator therapy in premenopausal breast cancer patients. J Gynecol Obstet Hum Reprod,2021,50(8):101929.
[11]Lee M, Piao J, Jeon MJ. Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with tamoxifen. Yonsei Med J,2020,61(4):317-322.
[12]田昭,翟庆杰,赖晋,等.伴乳腺癌史绝经后女性发生子宫内膜病变的影响因素分析.中国妇产科临床杂志,2022,23(6):579-582.
[13]祁晓莉,马秀华,周蓉,等.微量子宫内膜活检在子宫内膜癌及癌前病变筛查中的应用价值.中国妇产科临床杂志,2017,18(5):401-403.
[14]俞梅,向阳,马晓欣,等.子宫内膜癌筛查规范建议.中华妇产科杂志,2020,55(5):307-311.
[15]NakagawaOkamura C, Sato S, Tsuji I, et al. Effectiveness of mass screening for endometrial cancer. Acta Cytol,2002,46(2):277-283.
[16]Sasaki LMP, Andrade KRC, Figueiredo A, et al. Factors associated with malignancy in hysteroscopically resected endometrial polyps: A systematic review and metaanalysis. J Minim Invasive Gynecol,2018,25(5):777-785.
[17]Silva FR, Grande AJ, Lacerda Macedo AC, et al. Metaanalysis of breast cancer risk in levonorgestrelreleasing intrauterine system users. Clin Breast Cancer,2021,21(6):497-508.
[18]Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: A systematic review. Climacteric,2011,14(6):622-632.
[19]Yang BY, Gulinazi Y, Du Y, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertilitysparing treatment in patients with atypical endometrial hyperplasia and welldifferentiated endometrial cancer: A randomised controlled trial. Bjog,2020,127(7):848-857.
[20]Osman M, Muqbel T, Abduallh A, et al. Metformin therapy and breast cancer incidence in the Ha’il Region. Healthcare (Basel),2023,11(3):321.
[21]中国抗癌协会肿瘤内分泌专业委员会.乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南(2021年版).中国实用妇科与产科杂志，2021,8(37):815-820.
[22]Guo R, Si J, Xue J, et al. Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999-2017. Chin J Cancer Res,2019,31(4):653-662.
[23]Yang Y, Liu J, Peng M, et al. Introduction of a multicenter online database for nonmetastatic breast cancer in China. Sci China Life Sci,2020,63(9):1417-1420.
[24]Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res,2000,2(5):335-344.
[25]Price S, Bender SG, Yahn R, et al. Searching for an ideal SERM: Mining tamoxifen structureactivity relationships. Bioorg Med Chem Lett,2021,52:128383.
[26]Downton T, Zhou F, Segara D, et al. Oral selective estrogen receptor degraders(SERDs) in breast cancer: Advances, challenges, and current status. Drug Des Devel Ther,2022,16:2933-2948.
[27]Conlan MG, de Vries EFJ, Glaudemans A, et al. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy postmenopausal women. Eur J Drug Metab Pharmacokinet,2020,45(5):675-689.
[28]Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptorpositive breast cancer. J Clin Oncol,2023,41(20):3565-3575.
[29]Dorling L, Carvalho S, Allen J, et al. Breast cancer risk genesassociation analysis in more than 113,000 women. N Engl J Med,2021,384(5):428-439.
[30]Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1 or BRCA2mutated breast cancer. N Engl J Med,2021,384(25):2394-2405.